Shingrix logo

Product menu

Senior woman looking out of the window
1 in 4 people will develop shingles in their lifetime.1

Hear more about the impact of shingles, from real patients like DeAnn. 

DeAnn's story

Help to protect against shingles for patients like DeAnn.

SPEAK TO A MEMBER OF OUR TEAM

More information on SHINGRIX

Efficacy Icon – 90%

How efficacious is SHINGRIX?

SHINGRIX demonstrated >90% efficacy against shingles in adults 50 years of age and older based on pooled data from two large, phase 3 randomised controlled trials.2,3,4,5

View efficacy data

Cartoon virus icon

Addressing age-related decline in immunity.

SHINGRIX – specifically formulated to help address age-related decline in varicella zoster virus specific immunity in adults 50 years of age and older.2,3,6,7

UNDERSTAND THE SCIENTIFIC RATIONALE

Two syringe icon

Ready to vaccinate with SHINGRIX?

Familiarise yourself with the dosing and administration of SHINGRIX.2,3

Dosing and administration info

References

  1. DH Green Book ch 28a - Shingles. August 2021
  2. Shingrix, GB Summary of Product Characteristics (SPC)
  3. Shingrix, NI Summary of Product Characteristics (SPC)
  4. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372 (22):2087-96.
  5. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375 (11):1019-32.
  6. Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella- zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014 Mar;32 (15):1745-53.
  7. Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, Heineman TC. A phase 1 /2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. 2012 Oct;206 (8):1280-90.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

SHINGRIX is owned by or licensed to the GSK group of companies.
© 2022 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

October 2022 | PM-GB-SGX-WCNT-220011 (V3.0)